Literature DB >> 21920625

PET scans in radiotherapy planning of lung cancer.

Dirk De Ruysscher1, Ursula Nestle, Robert Jeraj, Michael Macmanus.   

Abstract

Accurate delineation of the primary tumor and of involved lymph nodes is a key requisite for successful curative radiotherapy in non-small cell lung cancer (NSCLC). In recent years, it has become clear that the incorporation of FDG PET-CT scan information into the related processes of patient selection and radiotherapy planning has lead to significant improvements for patients with NSCLC. The use of FDG PET-CT information in radiotherapy planning allows better target volume definition, reduces inter-observer variability and encourages selective irradiation of involved mediastinal lymph nodes. PET-CT also opens the door for innovative radiotherapy delivery and the development of new concepts. However, care must be taken to avoid a variety of technical pitfalls and specific education is necessary, for clinicians and physicists alike.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21920625     DOI: 10.1016/j.lungcan.2011.07.018

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  33 in total

1.  FDG PET/CT metabolic tumour volume in small-cell lung cancer: better staging and prognostic stratification for an improved therapeutic strategy.

Authors:  Giovanni Luca Ceresoli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06       Impact factor: 9.236

2.  Variability of ¹⁸F-FDG-positive lung lesion volume by thresholding.

Authors:  Eric Laffon; Henri de Clermont; Roger Marthan
Journal:  Eur Radiol       Date:  2012-10-20       Impact factor: 5.315

Review 3.  The role of texture analysis in imaging as an outcome predictor and potential tool in radiotherapy treatment planning.

Authors:  S Alobaidli; S McQuaid; C South; V Prakash; P Evans; A Nisbet
Journal:  Br J Radiol       Date:  2014-07-23       Impact factor: 3.039

Review 4.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

Review 5.  The imaging of small pulmonary nodules.

Authors:  Zejun Zhou; Ping Zhan; Jiajia Jin; Yafang Liu; Qian Li; Chenhui Ma; Yingying Miao; Qingqing Zhu; Panwen Tian; Tangfeng Lv; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2017-02

Review 6.  The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer.

Authors:  Sara Volpi; Jason M Ali; Angela Tasker; Adam Peryt; Giuseppe Aresu; Aman S Coonar
Journal:  Ann Transl Med       Date:  2018-03

7.  Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Authors:  Mitchell Machtay; Fenghai Duan; Barry A Siegel; Bradley S Snyder; Jeremy J Gorelick; Janet S Reddin; Reginald Munden; Douglas W Johnson; Larry H Wilf; Albert DeNittis; Nancy Sherwin; Kwan Ho Cho; Seok-Ki Kim; Gregory Videtic; Donald R Neumann; Ritsuko Komaki; Homer Macapinlac; Jeffrey D Bradley; Abass Alavi
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

8.  Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability.

Authors:  Ralph T H Leijenaar; Sara Carvalho; Emmanuel Rios Velazquez; Wouter J C van Elmpt; Chintan Parmar; Otto S Hoekstra; Corneline J Hoekstra; Ronald Boellaard; André L A J Dekker; Robert J Gillies; Hugo J W L Aerts; Philippe Lambin
Journal:  Acta Oncol       Date:  2013-09-09       Impact factor: 4.089

Review 9.  PET in the management of locally advanced and metastatic NSCLC.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

Review 10.  Emerging developments of chemoradiotherapy in stage III NSCLC.

Authors:  Allan Price
Journal:  Nat Rev Clin Oncol       Date:  2012-08-28       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.